In AR-positive LNCaP prostate cancer cells, 5α-dihydrotestosterone (DHT) significantly increased the expression levels of ASCT2 and glutaminase (GLS), the enzyme responsible for the deamination of glutaminase to glutamate. Here, SLC1A5 is linked to prostate carcinoma.